Efficacy of Cosmetic Product RV3278B-OS0386 on Skin Surface Ecosystem, in Teenagers with Mild to Moderate Facial Acne

An Exploratory Randomized Comparative Study to Evaluate the Effect of RV3278B-OS0386 on Skin Ecosystem, in Teenagers with Mild to Moderate Facial Acne

The aim of this exploratory study is to better understand the mechanisms of action of the RV3278B-OS0386 cosmetic product on the cutaneous ecosystem, in acne context.

Study Overview

• Status: Completed
• Conditions: Acne
• Intervention / Treatment: Other: RV3278B-OS0386; Other: RV4632A-RY1845

Detailed Description

This study will be conducted as an exploratory monocentric, randomized, comparative study.

A total number of 52 subjects (teenagers with mild to moderate facial acne) will be included and randomized in two parallel groups :

• The tested group who will apply the tested product RV3278B-OS0386

• The control group who will not apply the tested product. However, they will receive the associated product (RV4632A-RY1845), to be applied in the event of facial skin discomfort only.

  3 visits are planned:

  • Visit 1 (Day 1) : Inclusion, randomization, collection of biological samples on the forehead and start of product application.
  • Visit 2 (Day 29 +/- 3 days) : Phone call follow-up
  • Visit 3 (Day 57, a window of + 3 days is allowed): End-of-study visit - Collection of biological samples on the forehead.

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Romania
  • Bucharest, Romania, 011607
    • CIDP Romania

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Criteria related to the population:

• Female and male aged between 12 and 17 years included
• Subject having signed his/her written informed consent/assent for his/her participation in the study
• Subject whose parent(s) or guardian(s) has (have) given his/her (their) written consent for their child's participation in the study
• Subject affiliated to a social security system or health insurance, or is a beneficiary
• Subject whose parent(s) or guardian(s) is (are) registered with health social security or health insurance
• Subject and/or parents certifying the truth of the personal information declared to the investigator
• Cooperative subject and/or parent(s)/legal representative(s), aware of the necessity and duration of controls so that perfect adhesion to the protocol established by the clinical trial centre could be expected
• Subject with phototype I, II, III, IV according to the Fitzpatrick scale

• For woman/girl of childbearing potential:

  • use of an effective method of contraception, as assessed by the investigator, introduced and unchanged for at least 1 month (3 months in case of hormonal contraception) before inclusion in the study
  • accept to go on using it during the whole duration of the study

Criteria related to the skin condition (acne):

• Subject with combination, combination to greasy skin tendency or oily skin on face
• Subject with mild to moderate acne vulgaris on face; GEA from 2 to 3
• Subject with predominantly non-inflammatory acne on the forehead
• Subject with at least 20 open comedones on the face, excluding the nose area, at the inclusion

Subject presenting on his/her forehead (extension possible to the temples, but excluding the hair): target areas suitable for study samplings and measurements:

Inclusion criteria required for at least 26 subjects:

• Subject having a sensitive skin, according to his/her own self-assessment

Criteria related to the treatments and/or products:

• Subject who used the same facial cleansing product, shaving products, make-up (if applicable) for at least 1 month before inclusion and is willing to keep it during the whole duration of the study

Non Inclusion Criteria:

Criteria related to the population:

• Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing and to report required information in writing in his/her diary
• Subject whose parent(s) or guardian(s) is(are) unable to understand the information given (for linguistic or psychiatric reasons) and to give his/her consent in writing
• For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study
• Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship
• Subject whose parent(s) or guardian(s) who has forfeited his/her freedom by administrative or legal decision or under guardianship
• Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency
• Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements
• Subject whose parent(s) or guardian(s) is(are) unable to comply with study-related constraints
• Subject admitted in a sanitary or social facility
• Subject planning an hospitalization during the study
• Subject who is currently participating, who plans to participate or who has participated within the previous weeks or months in another clinical study liable to interfere with the study assessments according to the investigator's assessment
• Subject is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician,…), of the investigational site

Criteria related to the subject's health / skin condition:

• Subject with history of allergy or intolerance to any of the study products ingredients
• Subject with history of allergy or intolerance to any material used for the research (like pen, pencil, marker pen, sticking plaster…)
• Subject having any other dermatologic condition than acne, or characteristics (like tattoo) on the study area(s) liable to interfere with the study assessments
• Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
• Presence of more than an acne inflammatory nodule in the whole face
• Clinical signs of hormone dysfunction or hyperandrogenism
• Severe form of acne (acne conglobate, acne fulminans or nodulocystic acne) or acneiform eruptions, in the investigator's opinion
• Exposure to UV-Rays or excessive exposure to sunlight within the previous month

Criteria related to treatments and/or products:

• Any surgery, chemical (e.g.: skin peel) or physical treatment on the face in the 12 months before the inclusion visit or planned during the study
• Systemic isotretinoin treatment taken in 6 months before the inclusion or planned during the study
• Systemic acne treatment (e.g., zinc gluconate, antibiotics, hormonal treatment [excluding contraception] …] taken in the 3 months before the inclusion or planned to be taken during the study
• Probiotics taken orally in the month before the inclusion or planned to be taken during the study
• Use of self-tanning product on the face in the month before the inclusion or planned to be used during the study
• Topical acne treatment (e.g., benzoyl peroxide, vitamin A and its derivates) applied on the face in the month before the inclusion or planned during the study
• Topical or systemic Non-Steroidal Anti-Inflammatory (NSAI), corticosteroids, taken or applied to the face in the 2 weeks before the inclusion or planned to be taken/applied during the study
• Change in subject's usual make-up, facial hygiene habits, cleansing products, care products, shaving products and/or use new products on the face in the 2 weeks before the inclusion visit or planned during the study
• Skincare product for acne (e.g., product containing any ingredient, like "anti-blemish" active ingredient, liable to interfere with the study according to investigator's assessment) applied to the face in the 2 weeks before the inclusion visit or planned to be applied during the study
• Home care on the face (including exfoliation, masks, home peels, etc.) used in the 2 weeks before the inclusion visit or planned to be used during the study
• Any topical or systemic treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the assessments performed during the study according to the investigator's opinion
• Last face shaving performed in the 2 days before the inclusion visit
• Any topical treatment or product (including make-up) applied to the face between the last wash (performed the day before the visit) and the inclusion visit
• Water applied on the face within 8 hours before the inclusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Group; This group will apply the RV3278B-OS0386 cosmetic product for acne prone skin.	Other: RV3278B-OS0386; Cosmetic product to be applied twice a day on the face during the whole study
Other: Control Group; This group will receive the associated cosmetic product RV4632A-RY1845 (emollient cream), to be applied in the event of facial skin discomfort only.	Other: RV4632A-RY1845; Cosmetic product to be applied in the event of facial skin discomfort only

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of the RV3278B on acne severity	Assessed by the investigator on a 6-point scale (0 to 5 with 0: clear and 5: very severe)	Change from Visit 1 (Day 1) to Visit 3 (Day 57).
Effect of the RV3278B on open comedones.	Quantification of open comedones	Change from Visit 1 (Day 1) to Visit 3 (Day 57).
Effect of the RV3278B on biological criteria within isolated comedones	Analyses of comedone composition	Change from Visit 1 (Day 1) to Visit 3 (Day 57).
Effect of the RV3278B on biological criteria from the skin surface	Analyses of skin microbiota	Change from Visit 1 (Day 1) to Visit 3 (Day 57).
Effect of the RV3278B on biometrological criteria	Skin potential hydrogen measurement by pH meter	Change from Visit 1 (Day 1) to Visit 3 (Day 57).
Adverse events related to RV3278B	Adverse events occurrence will be determined by the subject's/parent(s) or guardian(s) spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation	From Visit 1 (Day 1) to Visit 3 (Day 57)

Secondary Outcome Measures

Outcome Measure	Time Frame
Illustrative Outcome : Standardized photographs of the subject's face	Visit 1 (Day 1) to Visit 3 (Day 57).

Collaborators and Investigators

• Sponsor: Pierre Fabre Dermo Cosmetique

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2024
• Primary Completion (Actual): March 6, 2025
• Study Completion (Actual): March 6, 2025

Study Registration Dates

• First Submitted: October 21, 2024
• First Submitted That Met QC Criteria: October 24, 2024
• First Posted (Actual): October 26, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 12, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Skin ecosystem; cosmetic care product
• Additional Relevant MeSH Terms: Skin Diseases; Acneiform Eruptions; Sebaceous Gland Diseases; Acne Vulgaris
• Other Study ID Numbers: RV3278B20240316

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No